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Objective: Non-adherence to medication is common among coronary heart disease patients. Non-adherence to
medication may be either intentional or unintentional. In this analysis we provide estimates of intentional and
unintentional non-adherence in the year following an acute coronary syndrome (ACS).
Method: In this descriptive prospective observational study of patients with conﬁrmed ACS medication adher-
ence measures were derived from responses to the Medication Adherence Report Scale at approximately
2 weeks (n = 223), 6 months (n = 139) and 12 months (n = 136) following discharge from acute treatment
for ACS.
Results: Totalmedication non-adherencewas 20%, 54% and 53% at each of these time points respectively. The cor-
responding ﬁgures for intentional non-adherence were 8%, 15% and 15% and 15%, 52% and 53% for unintentional
non-adherence. There were signiﬁcant increases in the levels of medication non-adherence between the imme-
diate discharge period (2 weeks) and 6 months that appeared to stabilize between 6 and 12 months after acute
treatment for ACS.
Conclusion:Unintentional non-adherence tomedicationsmay be the primary form of non-adherence in the year
followingACS. Interventions delivered early in the post-dischargeperiodmay prevent the relatively high levels of
non-adherence that appear to become established by 6 months following an ACS.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Medication adherence refers to the extent to which taking medica-
tion correspondswith agreed recommendations from a health care pro-
vider [1]. Non-adherence is a particular problem in patients diagnosed
with conditions related to cardiovascular disease (CVD), as long-term
pharmacotherapy is a central part of the medical management of CVD
[2]. A recent meta-analysis of 44 cohort studies consisting of almost
2 million participants found that 60% had good adherence (≥80%) to
CVDmedications [3]. This study was also able to estimate that approxi-
mately 9% of all CVD acute eventsmay be attributable to poor adherence
and therefore conﬁrms the ﬁndings from earlier reviews indicating that
non-adherence is a signiﬁcant barrier to reducing the public health im-
pact of CVD [4,5].al University of Ireland Galway,
355.
y).
. This is an open access article underMedication adherence has received intensive study from both be-
havioural and clinical scientists for several decades now [6] and both
theories of medication taking [7–9] and measurement strategies have
developed in this time [10,11], however this has not led to the identiﬁ-
cation of standardised and reliable intervention techniques that can im-
prove medication adherence [12]. One possible explanation for the
limited efﬁcacy of interventions is the imprecise characterisation of
non-adherence in terms of the stability of the problem and the extent
to which this behaviour is intentional as opposed to unintentional
[13]. Intentional non-adherence refers to non-adherence that is deliber-
ate and largely associated with patient motivation whereas uninten-
tional non-adherence is non-adherence that is largely driven by a lack
of capacity or resources to take medications [14]. However it is impor-
tant to acknowledge that the reasons underlying intentional and unin-
tentional non-adherence are not entirely independent in that certain
types of unintentional non-adherence e.g. forgetting, are logically
more likely when motivation for medication is low.
Studies of non-adherence tomedication following acute CVD events
such as acute coronary syndrome (ACS) have often neglected thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Characteristics of the study sample at 12 month follow-up
12 month sample
n = 136
Non-responders
at 12 months
n = 162
P
Mean (SD) n (%) Mean (SD) n (%)
Demographic factors
Age 61.19 (11.12) 59.28 (11.91) .16
Gender
Men 116 (85) 134 (83)
Women 20 (15) 28 (17) .55
Marital status
(married)
94 (69) 109 (67) .74
Educational
attainment
Basic 72 (53) 86 (53)
Secondary 43 (32) 50 (31)
Degree 20 (15) 26 (16) .95
Ethnicity (white) 120 (88) 127 (78) .03
Social deprivation
Low 101 (75) 87 (54)
Medium 22 (16) 48 (30)
High 11 (8) 25 (16) b .01
Clinical factors
ACS type
STEMI 118 (87) 142 (88)
NSTEMI/UA 18 (13) 20 (12) .82
Grace score 94.79 (25.61) 91.22 (29.36) .27
Previous MI 20 (15) 19 (12) .46
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Fig. 1. Percentage of patients reporting medication non-adherence by type in the year
following acute coronary syndrome.
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much of this literature to disaggregate the temporal stability and nature
of non-adherence is problematic, as these represent distinct behaviour-
al phenomena that may have different determinants [13,15] and there-
fore require different intervention strategies [16]. It is important
therefore to know what is the extent of these types of non-adherence
in the immediate and post-discharge period. This paper therefore aims
to add important descriptive information on medication adherence by
answering 2 questions:
1. What is the extent of intentional and unintentional non-adherence
to medication in the year following ACS?
2. Does the overall rate of medication non-adherence change signiﬁ-
cantly in the year following an ACS?
Methods
Participants were 223 patients with ACS admitted to St. George's
Hospital in South London between June 2007 and October 2008 taking
part in a larger study of biological factors and emotional adjustment
(N = 298), the Tracking Recovery after Acute Coronary Events (TRACE)
study which is reported in detail elsewhere [17,18]. The TRACE study
was approved by the Wandsworth Research Ethics Committee, and
written consent was obtained from all participants.
Medication adherence was measured using a 5 item scale, the Med-
ication Adherence Report Scale (MARS-5) [19], which is a widely used
measure that has established reliability and validity [8,9,20]. Respondents
indicate how often they engage in the ﬁve non-adherent behaviours on a
1–5 frequency scale (always, often, sometimes, rarely, never). Cronbach's
α for this scale averaged at 0.64 in the present study. As item1 (I forget to
take my medicines) referred to unintentional non-adherence and items
2–5 refer to intentional non-adherence, two separate measures could
be derived from this scale. Categorical non-adherence was deﬁned
as reporting any non-adherence on the MARS. Dichotomizing self-
reported adherence in this way was for descriptive purposes and
this approach is often taken in this literature due to the skewed,
non-normal distributions of medication adherence data [9] and the po-
tential for under-reporting for non-adherence [1].
Patients were interviewed in their homes an average of 21.6 days
following admission. Clinical details were obtained from medical notes
about cardiovascular history, clinical factors during admission and
management. A range of psychological measures and standard socio-
demographic measures including age, gender, marital status, education
and ethnicity were recorded. Follow-upmeasures of medication adher-
ence using theMARS were collected by postal questionnaire at approx-
imately 6 and 12 months following initial discharge.
In order to compare those providing medication adherence data at
12 monthswith those thatwere recruited into the larger study at baseline
independent samples t-tests were used to test for signiﬁcant differ-
ences in means for continuous variables and Chi-square tests for
non-independence for categorical variables. As the continuous medica-
tion non-adherence data from the MARS was signiﬁcantly negatively
skewed at the three time points Wilcoxon Signed Rank Tests were
used to test whether there was a signiﬁcant difference in medication
non-adherence over time.
Results
The characteristics of the sample at 12 months are summarized in Table 1. Non-
responders were more likely to be from ethnic minority groups and to have higher levels
of social deprivation. There were no other signiﬁcant differences observed between those
recruited in the larger study [17,18] and thosewhoprovidedmedication adherence data at
12 months. Fig. 1 presents the breakdown of medication non-adherence for all partici-
pants included at each time point by total, intentional and unintentional non-adherence
at 2 weeks, 6 months and 12 months post-discharge. TheWilcoxon Signed Rank Tests re-
vealed that there was a signiﬁcant increase in total medication non-adherence (measured
continuously) between 2 weeks and 6 months (Z = −5.163, P b 0.01) and between
2 weeks and 12 months (Z = −10.34, P b 0.01). There was no signiﬁcant differencebetween medication adherence (measured continuously) at 6 and 12 months
(Z = −0.29, P = 0.77).
Discussion
These results show that unintentional non-adherence may be the
primary form of non-adherence in the year following an ACS, as this
type of non-adherence was reported over 3 and a half times more fre-
quently at 6 and 12 months. Other studies of older adults withmultiple
co-morbidities [15] and patients with hypertension [13] have also iden-
tiﬁed similar patterns of non-adherence to medication. The study also
revealed that overall non-adherence was higher than estimates from
more objective measurement [3] and that non-adherence signiﬁcantly
increases between the immediate discharge period and at 6 months be-
fore stabilizing.
These ﬁndings suggest that behaviour change techniques that focus
on establishing a medication taking routine or habit [16] early in the
discharge period might help reduce the relatively high levels of non-
adherence that appear to become established by 6 months. Recent evi-
dence in the context of a hypertension medication regimen has shown
that medication ‘habit strength’ was the strongest predictor of a range
of self-report and electronic monitoring of medication adherence [20].
432 G.J. Molloy et al. / Journal of Psychosomatic Research 76 (2014) 430–432It is possible therefore that strengtheningmedication taking habits may
offer a counterbalance against higher level cognitive processes or ﬂuctu-
ations in emotional distress that could interfere with adherence [16],
however further empirical investigation is required to reliably test this
hypothesis.
There are a number of caveats that should be considered in relation to
this study. First, the self-report measure of non-adherence has a number
of obvious limitations and in particular the likelihood of reporting biases
[2] e.g. social desirability or recall biases. Indeed it is possible that social
desirability bias was more likely at the ﬁrst two week measurement
point due to the nature of the in home face-to-face interview. It is gener-
ally agreed however that all available adherence measures have their
strengths and limitations, therefore there is no consensus onwhat consti-
tutes a gold standard [1], nor is it clear hownon-adherence intentionality
can be assessedwithout self-report. Second, this is a relatively small sam-
ple of ACS patients from a single centre in a publically funded national
health service, therefore there are limitations in termsof external validity.
Finally therewas evidence of attrition bias in the samplewith those from
ethnic minority groups and those living in greater social deprivation
more likely to be non-responders at 12 months.
Nevertheless this is the ﬁrst study to look at levels of intentional and
unintentional non-adherence in ACS patients and these results provide
new information on the extent and stability of intentional and non-
intentional non-adherence in the year following acute treatment. In
particular the current ﬁndings would suggest that the future design of
interventions to improve adherence to medication should pay particu-
lar attention to unintentional aspects of non-adherence and the selec-
tion of particular behaviour change techniques [21] that address this
speciﬁc issue may lead to the design of more effective interventions
than currently exist [12].
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